## GLUCOSE AGENTS PRIOR AUTHORIZATION REQUEST

## PRESCRIBER FAX FORM

ONLY the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit <u>https://www.bcbstx.com/provider/medicaid/rx\_prior\_auth.html</u>

PATI	ENT AND INSURANCE	<b>INFORMATI</b>	ON			Today	/'s Date:			
Pat	ient Name (First):	Last:				M:	DOB (mm/d	d/yyyy):		
Patient Address:		City, State, Zip:	City, State, Zip:		Pat	Patient Telephone:				
BCE	3STX ID Number:		•		Group Number:					
PRE	SCRIBER/CLINIC INFOR									
			Prescriber NPI#:	Prescriber NP1#:		Specialty:		Contact Name:		
Clinic Name:				Clinic Address:						
City, State, Zip:				Phone #:		S	Secure Fax #:			
	ASE ATTACH ANY ADD		ORMATION THAT S	SHOUL			TH THIS RE	OUEST		
	ient's Diagnosis – ICD co									
Me	Medication Requested: Strength:									
Dosing Schedule: Quantity per Month:										
1.	Is the patient currently to If yes, when was treatm								🗆 No	
2.	Is the patient currently b								🗆 No	
	If yes, please specify agent:									
3.										
	Prenatal vitamins									
	Oral steroids – e.g. hydrocortisone, methylprednisolone, prednisone									
	Antipsychotics – e.g. risperidone, quetiapine, olanzapine									
	Oral oncology medications – e.g. Afinitor, Lenvima, Gleevec, Tarceva									
	Thyroid medications- e.g. Synthroid, levothyroxine, methimazole, propylthiouracil									
4.	Other, please sp Does the patient have g	pecify:	•						□ No	
ч.	If yes, when is the expe							103		
5.								 □ Yes	□ No	
5.										
6.	If yes, does the patient have one of the following (measured within the past 6 months) Yes No a. HbA1C ≥ 5.7% b. Fasting plasma glucose ≥100 mg/dL c. Oral Glucose Intolerance Test ≥ 140 mg/dL **Lab reports are required** The preferred products are made by Lifescan/OneTouch. Does the patient have limitations of use of the preferred glucose									
	test/strip/disk or meter?							🗌 Yes	🗆 No	
	<b>If yes</b> , please explain:									
7.	Is the request for a non-								🗆 No	
	If yes, does the insulin	pump or con	tinuous glucose mon	itoring	(CGM) device no	taccom	modate a			
	preferred glucose test st			•	. ,			🗌 Yes	🗆 No	
8.	Does the patient have a	-							□ No	
	Please continue to Pag				-		•••			

Patient Name (First): Last:			M: DOB (mm/dd/yyyy):									
9.	Does the patient have a disa	Does the patient have a disability which requires a non-preferred glucose test strip/disk and meter? Yes No										
10.	Please list all reasons for selecting the requested <b>agent</b> over alternatives (e.g., contraindications, allergies or history of adverse											
	drug reactions to alternatives).											
11. Please list all other agents the patient is <b>currently taking for treatment of this diagnosis</b>												
12.	12. Please list the agents the patient has previously tried and failed for treatment of this diagnosis. (Please specify if											
	brand name, generic, extended-release products, or OTC products.)											
		Date(s):	· · ·	Date(s):								
			Date(s):									
			Date(s):									
Prescriber or Authorized Signature: Date: Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient. Note: Payment is subject to member eligibility. Authorization does not guarantee payment.												
Prin 290 Eag	ase fax or mail this form to: The Therapeutics LLC, Clinical R Ames Crossing Road an, Minnesota 55121 LL FREE		<b>CONFIDENTIALITY NOTICE:</b> This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.									
гах	:: 877.243.6930 Phon	e: 855.457.0407										